Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2
This new publication from Novartis in collaboration with public health and academic researchers in Finland and the US adds to the evidence-base on how narcolepsy might have been triggered in genetically susceptible individuals.
Update on narcolepsy cases associated with Pandemrix vaccination in 2009 in the Netherlands
In November 2014, the Pharmacovigilance Centre of Netherlands (Lareb) provided an updated overview of Dutch cases of narcolepsy reported to have a link to Pandemrix.
No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor in Childhood Narcolepsy after Pandemrix™ Vaccination Campaign in Finland
This is the first published study where an attempt has been made to understand the possible biological mechanisms behind development of narcolepsy following vaccination with Pandemrix™.
New Swedish Registry study confirms increased risk of narcolepsy in children and adolescents after vaccination with Pandemrix
This observational cohort study utilizing electronic health care records covering 5.8 million Swedes confirmed an increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents (<
Association of receipt of Pandemrix™ and narcolepsy in children and adolescents in the UK (England)
This is the sixth EU Member State reporting an association between the development of narcolepsy and vaccination with the AS03-adjuvanted influenza A H1N1 (2009) pandemic vaccine Pandemrix.
Narcolepsy and Pandemrix Vaccine – an association in adults as well as childrenArchived
In September 2010 Sweden and Finland noted a number of children had developed narcolepsy seemingly in association with having received the pandemic vaccine used almost exclusively in those countries (Pandemrix)
Report on the association between the 2009 pandemic vaccine (Pandemrix®) and narcolepsy – Republic of IrelandArchived
Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010 - Final Report of National Narcolepsy Study Steering Committee, Department of Health, Ireland
Association of childhood narcolepsy and cataplexy and receipt of a pandemic influenza vaccine in Finland in 2009-10 – First papers in a peer review journalArchived
A pair of linked papers from Finland concerning the above topic, one epidemiological and the second combining both clinical and epidemiological were published on March 28th in the open access journal, PLoS One.(1,2).
Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Pre-Term European Infants: A Randomized Phase IIIb StudyArchived
Results of this study demonstrated that the RIX4414 vaccine was well tolerated and immunogenic in pre-term European infants: more than 75% of infants had seroconverted 30-83 days after dose 2.
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate VaccineArchived
This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally.